1. Generics Bulletin
  2. >>Business
  3. >>Strategy

Diversified Sourcing And Sustainability Are Key For Centrient

CEO Rex Clements Also Highlights Importance Of Non-Price Procurement Criteria

 
• By Dave Wallace

After almost a year as CEO of Centrient, Rex Clements reflects on the company’s experiences operating amid a pandemic that has underlined the importance of a diversified supply chain, while also highlighting the firm’s sustainable manufacturing initiatives and calling for non-price criteria to be taken into account by procurement processes, in an exclusive interview with Generics Bulletin.

Three Arrows Red Blue Green
Diversity in sourcing is key to a robust supply chain, Clements says • Source: Shutterstock

Diversified sourcing throughout the pharmaceutical supply chain is key for the industry to emerge stronger from the coronavirus pandemic, Centrient CEO Rex Clements has set out to Generics Bulletin in an exclusive interview. Meanwhile, sustainable, efficient manufacturing and green procurement criteria, as well as a robust response to the risks of antimicrobial resistance, are also key priorities for the antibiotics, statins and anti-fungals producer.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Sandoz Slims Down Pembrolizumab Trial As Regulators Streamline Requirements

 
• By Dave Wallace

As Sandoz continues development of its planned pembrolizumab biosimilar rival to Keytruda, the company has revealed plans to slim down its Phase III trial amid the latest moves from regulators towards streamlining clinical study requirements for biosimilar registration.

BGMA Becomes Medicines UK

 
• By Dave Wallace

The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By Dave Wallace

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Speranza Starts Generics Offshoot In Response To Wider US Pharma Manufacturing Drive

 
• By Adam Zamecnik

Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.

More from Business

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By Dave Wallace

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Speranza Starts Generics Offshoot In Response To Wider US Pharma Manufacturing Drive

 
• By Adam Zamecnik

Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.